REAL-WORLD ECONOMIC IMPACTS OF ACUTE LYMPHOBLASTIC LEUKEMIA AND THEIR COST DRIVERS: INSIGHTS FROM STRUCTURAL EQUATION MODELING
Author(s)
Yuki Takumoto, Ph.D.1, Koki Idehara, Ph.D.2, Toshiaki Tsubota, Ph.D.1, Kenji Kanematsu, MSc1, Takunari Yoshinaga, MD., Ph.D.1.
1Gilead Sciences Japan, Tokyo, Japan, 2IQVIA Solutions Japan G.K., Tokyo, Japan.
1Gilead Sciences Japan, Tokyo, Japan, 2IQVIA Solutions Japan G.K., Tokyo, Japan.
OBJECTIVES: This retrospective study aimed to characterize healthcare cost, resource utilization (HCRU), and factors related to the economic impact of acute lymphoblastic leukemia (ALL) in Japan using a large hospital-based claims database.
METHODS: Patients of all ages diagnosed with ALL who initiated induction therapy between July 2015 and May 2025 were identified using Medical Data Vision Co., Ltd. The index date was the initiation of ALL induction chemotherapy. Patients were followed for ≥12 months to assess HCRU and costs. The population was stratified by tyrosine kinase inhibitors (TKI) use, reflecting Philadelphia chromosome status, and age. Structural equation modeling was applied to assess pathways linking baseline characteristics and follow‑up HCRU to patient costs. Costs were estimated in 2026 using an exchange rate of 1 USD = 157 JPY.
RESULTS: A total of 1,009 patients were identified and followed for a mean of 1,424 days (SD: 995.3). Of these, 54.8% (n = 553) were male, and 39.7% were aged ≥65 years (range: 0-94 years). Overall, 37.5% (n = 378) received TKI therapy as their index therapy, and 9.0% (n = 91) received allogeneic hematopoietic stem-cell transplantation (HSCT) during the follow-up period. Patients had a mean of 16.0 outpatient visits per year (SD: 11.0) and 2.5 hospitalizations annually (SD: 2.6). Among hospitalized patients, the mean annual cumulative length of stay was 76.8 days (SD: 73.9), and the mean total annual costs per patient was $54,053 (SD: $58,954). Preliminary SEM results suggested that HCRU associated with total costs was organized into several latent constructs, with latent factors related to hospitalization and medication uses presenting a major impact.
CONCLUSIONS: This study characterized healthcare costs and HCRU Japanese patients with ALL, as well as their relationship between several latent variables. These findings may support the optimization of healthcare resource allocation and the more improvement of treatment efficiency.
METHODS: Patients of all ages diagnosed with ALL who initiated induction therapy between July 2015 and May 2025 were identified using Medical Data Vision Co., Ltd. The index date was the initiation of ALL induction chemotherapy. Patients were followed for ≥12 months to assess HCRU and costs. The population was stratified by tyrosine kinase inhibitors (TKI) use, reflecting Philadelphia chromosome status, and age. Structural equation modeling was applied to assess pathways linking baseline characteristics and follow‑up HCRU to patient costs. Costs were estimated in 2026 using an exchange rate of 1 USD = 157 JPY.
RESULTS: A total of 1,009 patients were identified and followed for a mean of 1,424 days (SD: 995.3). Of these, 54.8% (n = 553) were male, and 39.7% were aged ≥65 years (range: 0-94 years). Overall, 37.5% (n = 378) received TKI therapy as their index therapy, and 9.0% (n = 91) received allogeneic hematopoietic stem-cell transplantation (HSCT) during the follow-up period. Patients had a mean of 16.0 outpatient visits per year (SD: 11.0) and 2.5 hospitalizations annually (SD: 2.6). Among hospitalized patients, the mean annual cumulative length of stay was 76.8 days (SD: 73.9), and the mean total annual costs per patient was $54,053 (SD: $58,954). Preliminary SEM results suggested that HCRU associated with total costs was organized into several latent constructs, with latent factors related to hospitalization and medication uses presenting a major impact.
CONCLUSIONS: This study characterized healthcare costs and HCRU Japanese patients with ALL, as well as their relationship between several latent variables. These findings may support the optimization of healthcare resource allocation and the more improvement of treatment efficiency.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE100
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Novel & Social Elements of Value
Disease
Oncology, Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)